Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
Background Patients with mastocytosis may suffer from severe hypotension after wasp or bee stings. In these patients, no specific IgE is detectable, but they usually have skin lesions and an elevated serum tryptase level. Methods We report on 6 patients who were referred to our department because of severe hypotension following bee or wasp stings without cutaneous lesions. Results In 3 patients, the baseline serum tryptase level was elevated (26, 36, and 67 ng/ml, respectively), and investigation of their bone marrow revealed systemic mastocytosis (SM). In the remaining 3 patients, serum tryptase levels were Conclusions All patients with unexplained hypotension after hymenoptera stings should undergo a thorough investigation for major and minor SM criteria regardless of the tryptase level or presence of skin lesions, in order to diagnose or exclude SM or a related subdiagnostic condition (1 or 2 minor SM criteria) tentatively termed monoclonal mast cell activation syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These patients suffer from a combination of primary and secondary MCAS, and, as a result, they are at high risk to develop recurrent life-threatening anaphylaxis (21-23).”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [22]
In the citing paper
“in patients with systemic mastocytosis (SM) and MCAS, an IgE-dependent allergy (e.g., against insect venom) is frequently documented.”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [22]
In the citing paper
“These patients as well as those with cutaneous mastocytosis (CM) or SM are both classified as primary (clonal) MCAS (Table 2).”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [22]
Citations
Cites
Hsu, S. M., Raine, L., & Fanger, H. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.4.6166661 · Cited by 14,140
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108 · cited 1×
“If at least one major and one minor or at least three minor SM criteria are fulfilled, the diagnosis SM is established [”
BackgroundSelf-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872 · cited 1×
“In the vast majority of these patients, the bone marrow is affected. In most SM patients, the somatic KIT mutation 2468A→T (D816V) is detectable [”
BackgroundTryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Establishment of an immature mast cell line from a patient with mast cell leukemia
Butterfield, J. H., Weiler, D., Dewald, G., & Gleich, G. J. (1988) · Leukemia Research · doi:10.1016/0145-2126(88)90050-1 · Cited by 737 · cited 1×
“The human MC leukemia cell line HMC-1, known to display the KIT mutation D816V [”
BackgroundLongley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H., & Modlin, I. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 607
Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW
TRAVIS, W. D., LI, C.-Y., BERGSTRALH, E. J., YAM, L. T., & SWEE, R. G. (1988) · Medicine · doi:10.1097/00005792-198811000-00001 · Cited by 488
Schwartz, L. B., Sakai, K., Bradford, T. R., Ren, S., Zweiman, B., Worobec, A. S., & Metcalfe, D. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118337 · Cited by 371
Classification and Diagnosis of Mastocytosis: Current Status
Metcalfe, D. D. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12468882 · Cited by 346
Research works printed but not linked: 3
- 10.1056%2fnejm199202273260912 · DOI
- 10.1016%2fs0091-6749%2897%2970314-2 · doi:10.1016/s0091-6749(97)70314-2 · Paper page
- 10.1159%2f000059404 · DOI · Paper page
Cited by
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,680
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationMast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Self-citationBonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Mast cell activation syndrome: Proposed diagnostic criteria
Akin, C., Valent, P., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.035 · Cited by 327
“The ability to diagnose this disorder was supported by a later report.(12) More recent studies documenting that patients with systemic hypotension associated with insect stings have mastocytosis or a monoclonal mast cell population further substantiated the concept.”
ResultSelf-citationÁlvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294
González de Olano, D., De La Hoz Caballer, B., Núñez López, R., Sánchez Muñoz, L., Cuevas Agustín, M., Diéguez, M. C., Álvarez Twose, I., Castells, M. C., & Escribano Mora, L. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02804.x · Cited by 245
Akin, C., Scott, L. M., Kocabas, C. N., Kushnir-Sukhov, N., Brittain, E., Noel, P., & Metcalfe, D. D. (2007) · Blood · doi:10.1182/blood-2006-06-028100 · Cited by 240
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., Nedoszytko, B., Siebenhaar, F., Sperr, W. R., Oude Elberink, J. N. G., et al. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.01.006 · Cited by 225
“In other patients, clonal KIT-mutated (CD25þ) MCs are detected, but only 1 or 2 minor SM criteria and no major SM criterion are found.(21,22,26-28) These patients as well as those with cutaneous mastocytosis (CM) or SM are classified as having primary (clonal) MCAS (Table II).”
BackgroundInfluentialSelf-citationEpidemiology, Prognosis, and Risk Factors in Mastocytosis
Brockow, K. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.01.003 · Cited by 195
Cardiovascular disease and anaphylaxis
Mueller, U. R. (2007) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328259c328 · Cited by 164
Theoharides, T. C., Tsilioni, I., & Ren, H. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1596800 · Cited by 120
The mastocytosis society survey on mast cell disorders: patient experiences and perceptions
Jennings, S., Russell, N., Jennings, B., Slee, V., Sterling, L., Castells, M., Valent, P., & Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2013.09.004 · Cited by 143
Self-citationGonzález‐de‐Olano, D., Álvarez‐Twöse, I., Esteban‐López, M. I., Sánchez‐Muñoz, L., de Durana, M. D. A. D., Vega, A., García‐Montero, A. C., Gonzalez-Mancebo, E., Belver, M. T., Herrero-Gil, M. D., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.010 · Cited by 138
Mastocytosis and insect venom allergy
Bonadonna, P., Zanotti, R., & Müller, U. (2010) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e32833b280c · Cited by 123
Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper
Bonadonna, P., Pagani, M., Aberer, W., Bilò, M. B., Brockow, K., Oude Elberink, H., Garvey, L., Mosbech, H., Romano, A., Zanotti, R., et al. (2015) · Allergy · doi:10.1111/all.12617 · Cited by 103
Zanotti, R., Lombardo, C., Passalacqua, G., Caimmi, C., Bonifacio, M., De Matteis, G., Perbellini, O., Rossini, M., Schena, D., Busa, M., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.035 · Cited by 123
Kucharik, A. H., & Chang, C. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08755-8 · Cited by 122
“However, the categories of primary MMAS and idiopathic MCAS are still unaccounted for.”
InfluentialMast cell activation syndromes: definition and classification
Valent, P. (2013) · Allergy · doi:10.1111/all.12126 · Cited by 120
Self-citationDiagnosis of mast cell activation syndrome: a global "consensus-2"
Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., et al. (2021) · Diagnosis · doi:10.1515/dx-2020-0005 · Cited by 115
“In 2007, the first case reports were published [4, 5], followed shortly by a limited proposal for diagnostic criteria in cases where MC clonality could be identified [6].”
BackgroundEvaluation of the WHO criteria for the classification of patients with mastocytosis
Sánchez‐Muñoz, L., Álvarez‐Twöse, I., García‐Montero, A. C., Teodósio, C., Jara‐Acevedo, M., Pedreira, C. E., Matito, A., Morgado, J. M., Sánchez, M. L., Mollejo, M., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.84 · Cited by 105
Valent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., Arock, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239030 · Cited by 92
Self-citationValent, P., Hartmann, K., Bonadonna, P., Gülen, T., Brockow, K., Alvarez-Twose, I., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.05.007 · Cited by 90
Self-citationSchuch, A., & Brockow, K. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.017 · Cited by 88
The presence of mast cell clonality in patients with unexplained anaphylaxis
Gülen, T., Hägglund, H., Sander, B., Dahlén, B., & Nilsson, G. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12369 · Cited by 82
Picard, M., Junior, P. F. G.-B., Mezzano, V., & Castells, M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.04.001 · Cited by 81
“In both studies, KIT mutations could not be found on unsorted bone marrow samples, although all patients had bone marrow mast cells with an aberrant morphology (spindle shaped) and CD25 expression.(6,10) In 2009, Bonadonna et al(7) reported 9 patients ith MMAS diagnosed following a systemic reaction o hymenoptera stin…”
Gülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12410 · Cited by 75
Afrin, L. B., Butterfield, J. H., Raithel, M., & Molderings, G. J. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1161231 · Cited by 74
Epidemiology, Diagnosis, and Treatment of Hymenoptera Venom Allergy in Mastocytosis Patients
Niedoszytko, M., Bonadonna, P., Elberink, J. N. G. O., & Golden, D. B. K. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.02.004 · Cited by 75
Hymenoptera Allergy and Mast Cell Activation Syndromes
Bonadonna, P., Bonifacio, M., Lombardo, C., & Zanotti, R. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0582-5 · Cited by 74
Bonadonna, P., Zanotti, R., Pagani, M., Bonifacio, M., Scaffidi, L., Olivieri, E., Franchini, M., Reccardini, F., Costantino, M. T., Roncallo, C., et al. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.11.025 · Cited by 73
Carter, M. C., Metcalfe, D. D., Matito, A., Escribano, L., Butterfield, J. H., Schwartz, L. B., Bonadonna, P., Zanotti, R., Triggiani, M., Castells, M., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.063 · Cited by 72
Potier, A., Lavigne, C., Chappard, D., Verret, J. L., Chevailler, A., Nicolie, B., & Drouet, M. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03210.x · Cited by 71
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis
Zanotti, R., Bonadonna, P., Bonifacio, M., Artuso, A., Schena, D., Rossini, M., Perbellini, O., Colarossi, S., Chilosi, M., & Pizzolo, G. (2011) · Haematologica · doi:10.3324/haematol.2010.034553 · Cited by 61
“fulfilled less than three minor criteria but displayed MC clonality markers and were considered as having Monoclonal MC activation syndrome.(6,7) The major diagnostic criterion and at least one minor criterion were fulfilled on BM evaluation in 68.”
BackgroundBrockow, K., & Metcalfe, D. D. (2010) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000315946 · Cited by 62
Venom Immunotherapy in Patients with Mastocytosis and Hymenoptera Venom Anaphylaxis
González-de-Olano, D., Álvarez-Twose, I., Vega, A., Orfao, A., & Escribano, L. (2011) · Immunotherapy · doi:10.2217/imt.11.44 · Cited by 56
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1510021 · Cited by 63
Self-citationMastocytosis – A Disease of the Hematopoietic Stem Cell
Horny, H., Sotlar, K., Valent, P., & Hartmann, K. (2008) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2008.0686 · Cited by 62
Self-citationAnaphylaxis After Hymenoptera Sting: Is It Venom Allergy, a Clonal Disorder, or Both?
Castells, M., Hornick, J. L., & Akin, C. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.03.015 · Cited by 61
Anaphylaxis and Mast Cell Disease: What Is the Risk?
Akin, C. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-009-0080-8 · Cited by 61
Spectrum of mast cell activation disorders
Petra, A. I., Panagiotidou, S., Stewart, J. M., Conti, P., & Theoharides, T. C. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.906302 · Cited by 54
“4 ng/ml or greater than the upper limit of normal; in patients with previous hypotensive episodes and/or syncope; urticaria pigmentosa (UP) present in adult patients; unexplained or explained anaphylaxis provoked with hymenoptera sting even when specific IgE testing to hymenoptera is negative [46,48,49], indicating th…”
BackgroundMast cell activation syndromes: Collegium Internationale Allergologicum update 2022
Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524532 · Cited by 55
Self-citationAnaphylaxis as a clinical manifestation of clonal mast cell disorders
Matito, A., Alvarez-Twose, I., Morgado, J. M., Sánchez-Muñoz, L., Orfao, A., & Escribano, L. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0450-8 · Cited by 51
Anaphylaxis and Mast Cell Disorders
Gülen, T., & Akin, C. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.09.007 · Cited by 51
Valent, P., Horny, H.-P., Triggiani, M., & Arock, M. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000323763 · Cited by 50
Self-citationValent, P., Hartmann, K., Hoermann, G., Reiter, A., Álvarez‐Twöse, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., et al. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.08.044 · Cited by 49
Self-citationGreenhawt, M., & Akin, C. (2007) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3282a6443e · Cited by 47
Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction
Valent, P., & Akin, C. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.11.045 · Cited by 47
“17,18,29,30 As per de fi nition, these patients are also suffering from clonal (primary) MCAS, also termed monoclonal MCAS (MMAS) (Table I).”
Self-citationDiagnosis, progression patterns and prognostication in mastocytosis
Sperr, W. R., & Valent, P. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.12 · Cited by 40
Self-citationMast cell activation syndromes presenting as anaphylaxis
Akin, C. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.01.010 · Cited by 43
“or CD251 mast cells but do not meet the full WHO diagnostic criteria.(15,16) These patients present with symptoms of mast cell activation but lack skin lesions of urticaria pigmentosa.”
BackgroundZanotti, R., Bonifacio, M., Isolan, C., Tanasi, I., Crosera, L., Olivieri, F., Orsolini, G., Schena, D., & Bonadonna, P. (2021) · Cancers · doi:10.3390/cancers13246380 · Cited by 36
Butterfield, J., & Weiler, C. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.02.021 · Cited by 41
Nedoszytko, B., Niedoszytko, M., Lange, M., Van Doormaal, J., Gleń, J., Zabłotna, M., Renke, J., Vales, A., Buljubasic, F., Jassem, E., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2008.01827.x · Cited by 35
“Nine adult patients had CM, and two adult patients (2%) with typical mediator-related symptoms were found to fulfil only two minor SM criteria, a condition recently described as monoclonal MC activation syndrome (MMAS) (6, 28, 29).”
BackgroundSelf-citationSevere immediate type hypersensitivity reactions in 105 German adults: when to diagnose anaphylaxis.
Treudler, R., Kozovska, Y., & Jc, S. (2008) · PubMed · Cited by 40
Immunology and clinical manifestations of non-clonal mast cell activation syndrome
Cardet, J.-C., Castells, M. C., & Hamilton, M. J. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0326-8 · Cited by 39
“among other diagnostic considerations] [1, 40, 41], or unexplained anaphylaxis including that provoked with hymenoptera sting (especially in the setting of negative specific IgE testing to hymenoptera [42]).”
Mast cell activation disease and the modern epidemic of chronic inflammatory disease
Afrin, L. B. (2016) · Translational Research · doi:10.1016/j.trsl.2016.01.003 · Cited by 39
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives
Valent, P., Arock, M., Bonadonna, P., Brockow, K., Broesby‐Olsen, S., Escribano, L., Gleixner, K. V., Grattan, C. E. H., Hadzijusufovic, E., Hägglund, H., et al. (2012) · Wiener klinische Wochenschrift · doi:10.1007/s00508-012-0293-z · Cited by 38
“Apart from mediator-related symptoms, patients may also suffer from osteopenia or osteoporosis, gastrointestinal symptoms, neurological or psychiatric symptoms, or/and symptoms related to skin lesions such as pruritus or flushing [20–28].”
BackgroundSelf-citationClonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis
Kačar, M., Rijavec, M., Šelb, J., & Korošec, P. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14264 · Cited by 37
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis
MATTEIS, G. D., Zanotti, R., Colarossi, S., Benedittis, C. D., García‐Montero, A. C., Bonifacio, M., Sartori, M., Aprili, F., Caruso, B., Paviati, E., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.11.029 · Cited by 35
Russell, N., Jennings, S., Jennings, B., Slee, V., Sterling, L., Castells, M., Valent, P., & Akin, C. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.07.032 · Cited by 31
Self-citationBone Marrow Mastocytosis: A Diagnostic Challenge
Zanotti, R., Tanasi, I., Bernardelli, A., Orsolini, G., & Bonadonna, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071420 · Cited by 29
“The proposed diagnosis in these cases is monoclonal mast cell activation syndrome (MCAS) or pre-diagnostic SM [27,33,34].”
BackgroundJagdis, A., & Vadas, P. (2014) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.05.001 · Cited by 28
Insights in Anaphylaxis and Clonal Mast Cell Disorders
González‐de‐Olano, D., & Álvarez‐Twöse, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00792 · Cited by 28
(2023) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2023.07.001 · Cited by 25
Self-citationCurrent state of biology and diagnosis of clonal mast cell diseases in adults
ALVAREZ‐TWOSE, I., MORGADO, J. M., SÁNCHEZ‐MUÑOZ, L., GARCÍA‐MONTERO, A., MOLLEJO, M., ORFAO, A., & ESCRIBANO, L. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01427.x · Cited by 21
“reported which are generally termed as monoclonal MC activation syndromes [3, 21] or clonal MC activation disorders [19, 22].”
BackgroundMast Cell Activation Disease and Microbiotic Interactions
Afrin, L. B., & Khoruts, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.008 · Cited by 25
“Speculation about MC disease featuring constitutive activation without neoplasia emerged in 1991(6); case reports were first published in 2007.(7,8) Crucial insight into the marked clinical heterogeneity of relatively nonproliferative MC activation syndrome (MCAS) came with the discovery of many mutations in MC Kit mR…”
BackgroundA Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis
Gülen, T. (2023) · Diagnostics · doi:10.3390/diagnostics13213307 · Cited by 24
“Diagnostic criteria of systemic mastocytosis (SM) and monoclonal mast cell activation syndrome (MMAS) (adapted from references: [11,18,31,32]).”
BackgroundUsing the Right Criteria for MCAS
Gülen, T. (2024) · Current Allergy and Asthma Reports · doi:10.1007/s11882-024-01126-0 · Cited by 24
“Monoclonal mast cell activation syndrome (MMAS) is a newly recognized variant of clonal MC disorders and is characterized by severe episodes of anaphylaxis with hypotensive syncope in affected patients [87, 88].”
BackgroundPharmacotherapy of mast cell disorders
Gülen, T., & Akin, C. (2017) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000377 · Cited by 21
Presentation, diagnosis, and management of mast cell activation syndrome
Afrin, L. B. (2013) · Cited by 24
Perbellini, O., Zamò, A., Colarossi, S., Zampieri, F., Zoppi, F., Bonadonna, P., Schena, D., Artuso, A., Martinelli, G., Chilosi, M., et al. (2011) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20606 · Cited by 22
Utility of hydroxyurea in mast cell activation syndrome
Afrin, L. B. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-28 · Cited by 22
“This theory appeared validated when the first recognized cases of what is now called MC activation syndrome (MCAS) were published in 2007 [26-28].”
BackgroundEvaluation of mast cell activation syndromes: impact of pathology and immunohistology
Horny, H.-P., Sotlar, K., & Valent, P. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000336374 · Cited by 21
Self-citationMast Cell Activation Syndrome as a Significant Comorbidity in Sickle Cell Disease
Afrin, L. B. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000325 · Cited by 20
Gastrointestinal Involvement in Mast Cell Activation Disorders
Hsieh, F. H. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.008 · Cited by 17
Mast cell function in physiology and pathophysiology
Gerhard, J. (2010) · Cited by 17
Clonal Mast Cell Activation Syndrome with Anaphylaxis to Sulfites
Cifuentes, L., Ring, J., & Brockow, K. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000348379 · Cited by 17
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association
Bonadonna, P., Bonifacio, M., Lombardo, C., & Zanotti, R. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0550-0 · Cited by 17
Diagnosis of Adult Mastocytosis: Role for Bone Marrow Analysis
Escribano, L., García‐Montero, A. C., Sánchez‐Muñoz, L., Teodósio, C., Álvarez‐Twöse, I., Jara‐Acevedo, M., Morgado, J. M., Almeida, J., & Órfão, A. (2012) · Wiley eBooks · doi:10.1002/9781444398595.ch29 · Cited by 16
Afrin, L. B., Dempsey, T. T., & Weinstock, L. B. (2022) · Vaccines · doi:10.3390/vaccines10010127 · Cited by 17
“With the first cases of MCAS having been reported only about a decade ago [41,42] (two decades after the disease was first hypothesized to exist [43–45]), this syndrome remains unknown to most physicians, an unfortunate irony if the preliminary epidemiologic estimates of the disease’s great prevalence (up to 17–20% of…”
BackgroundSolomon, B. D., & Khatri, P. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.09.006 · Cited by 15
Mastocytosis: Advances in diagnosis and treatment
Hungness, S. I., & Akin, C. (2007) · Current Allergy and Asthma Reports · doi:10.1007/s11882-007-0037-8 · Cited by 15
“Recently, clonal mast cells have been identified in bone marrow aspirates of some patients with recurrent anaphylactic episodes [24, 25 ].”
BackgroundManagement of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis
Gülen, T. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.04.010 · Cited by 14
Brockow, K. (2013) · Der Hautarzt · doi:10.1007/s00105-012-2452-6 · Cited by 13
Mast cell activation syndrome in pregnancy, delivery, postpartum and lactation: a narrative review
Dorff, S. R., & Afrin, L. B. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1674259 · Cited by 11
Multiple bee stings, peritumoral mast cell degranulation and anaphylaxis – Is there a relationship?
Herbst, J. B., Heath, K. J., Heddle, R. J., Gilbert, J. D., & Byard, R. W. (2012) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2012.09.016 · Cited by 11
Mast cell diseases in patients with insect venom allergy: implications for diagnosis and therapy
Ruëff, F., Mastnik, S., & Oppel, E. M. (2017) · Allergo Journal International · doi:10.1007/s40629-017-0023-1 · Cited by 10
“A number of terms have been proposed for this phenomenon, of which only the most common will be referred to here: monoclonal mast cell activation syndrome (MMAS) [13].”
InfluentialVega-Castro, A., Alonso‐Llamazares, A., Cárdenas, R., Beitia, J., Mateo, B. A., Álvarez‐Twöse, I., & Blanco, C. (2018) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0258 · Cited by 10
“Therefore, clinical suspicion is mandatory for diagnosis [18,19].”
BackgroundMethodResultTHE PRESENTATION, DIAGNOSIS AND TREATMENT OF MAST CELL ACTIVATION SYNDROME
Afrin, L. B. (2014) · Cited by 10
Escribano, L., & Orfao, A. (2011) · Anaphylaxis and Hypersensitivity Reactions · doi:10.1007/978-1-60327-951-2_16 · Cited by 7
“In patients with recurrent anaphylaxis, who present with syncopal or near-syncopal episodes [29, 30] without associated hives or angioedema [31], mastocytosis needs to be ruled out.”
BackgroundProgress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years
Afrin, L. B., Blitshteyn, S., Bluestein, L. S., Dempsey, T. T., Maxwell, A. J., Miller, C. S., Nagy, È., Nugent, D. J., Schofield, J. R., Weinstock, L. B., et al. (2026) · Diagnosis · doi:10.1515/dx-2026-0016 · Cited by 7
“Two decades have passed since the fi rst case reports of MCAS [22, 23].”
When yellow jackets attack: Recurrent and severe anaphylactic reactions to insect bites and stings
Pollyea, D. A., George, T. I., Corless, C. L., & Gotlib, J. R. (2009) · American Journal of Hematology · doi:10.1002/ajh.21551 · Cited by 7
Gülen, T., Dahlén, B., Sander, B., Hägglund, H., & Nilsson, G. P. (2013) · Clinical and Translational Allergy · doi:10.1186/2045-7022-3-22 · Cited by 7
“The MMAS diagnosis was made in Case 1 since only 2 minor criteria was fulfilled (aberrant phenotype and KIT D816V mutation); whereas Case 2 received diagnosis of SM by fulfillment of 3 minor criteria (atypical mast cell morphology, aberrant phenotype and Kit D816V mutation).”
BackgroundInfluentialAnaphylaxis with clonal mast cells in normal looking skin – a new entity?
Bretterklieber, A., Beham‐Schmid, C., Sturm, G. J., Berghold, A., Brezinschek, R. I., Aberer, W., & Aberer, E. (2015) · Allergy · doi:10.1111/all.12634 · Cited by 6
Ballul, T., Sabato, V., Valent, P., Hermine, O., Lortholary, O., Rossignol, J., Ballul, T., Sabato, V., Livideanu, C. B., Neuraz, A., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103043 · Cited by 6
“9 – 11 They are classi fi ed as primary or clonal MCAS if they ful fi ll all criteria of MCAS (typical symptoms, +20% and +2 ng/ mL tryptase elevation during MCA episode, and response to MC stabilizing agent).”
InfluentialSelf-citationDiagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach
Lee, E. Y., & Picard, M. (2025) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-025-00998-9 · Cited by 4
Recent advances in mast cell clonality and anaphylaxis
Akin, C. (2009) · F1000 Medicine Reports · doi:10.3410/m1-97 · Cited by 4
“Approximately 62% of these patients with elevated tryptase levels satisfied the criteria for systemic mastocytosis, whereas 26.5% had MMAS.”
BackgroundInfluentialRaccomandazioni sull'uso della triptasi nella diagnosi dell'anafilassi e della mastocitosi
Platzgummer, S., Caponi, L., Sargentini, V., Visentini, D., Brusca, I., Bizzaro, N., Pesce, G., Bagnasco, M., Deleonardi, G., Caruso, B., et al. (2019) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.19.00022-7 · Cited by 4
Mastocytosis and Mast Cell Activation Syndromes Presenting as Anaphylaxis
Akin, C., & Metcalfe, D. D. (2011) · Anaphylaxis and Hypersensitivity Reactions · doi:10.1007/978-1-60327-951-2_15 · Cited by 4
Bone Marrow Expression of Mast Cell Disorders
Sánchez‐Muñoz, L., Henriques, A., Álvarez‐Twöse, I., & Matito, A. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.012 · Cited by 4
Metadata
- Authors
- Sonneck, K., Florian, S., Müllauer, L., Wimazal, F., Födinger, M., Sperr, W. R., & Valent, P.
- Affiliations
- Medical University of Vienna (AT)
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2006-10-20
- Volume
- 142
- Issue
- 2
- Pages
- 158-164
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2011616095
- Cited by
- 129
- References
- 40
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 8 · 2016: 3 · 2015: 11 · 2014: 9 · 2013: 8 · 2012: 7
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- International Archives of Allergy and Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- systemic mastocytosis, anaphylaxis, bee stings, wasp stings, hypotension, serum tryptase, bone marrow mast cells, mastocytosis diagnosis
- MeSH terms
- Anaphylaxis, Animals, Bees, Bone Marrow Cells, Female, Flow Cytometry, Humans, Hypotension, Immunohistochemistry, Insect Bites and Stings, Male, Mast Cells, Wasps, Mastocytosis, Systemic, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.